


unyvero

Unyvero's sample-to-answer platform provides rapid results for severe infectious diseases in hospitalized patients

Powerful multiplex PCR technology combined with the broadest range of microorganism and resistance targets sets the Unyvero System apart.


The Unyvero System consists of:

- Lysator to lyse and process a variety of native samples
- Cockpit to manage testing process, display, store, and transmit results
- Analyzer to perform DNA testing with random-access, multiplex PCR



A single test handles one patient sample, analyzes 40 DNA analytes and delivers reliable results within just 4-5 hours

unyvero  
a product by curetis




Unyvero is designed to expand with your growing needs

Applications for severe infections:

- Blood Culture – BCU
- Hospitalized Pneumonia – HPN
- Intra-Abdominal Infection – IAI
- Implant & Tissue Infection – ITI
- Urinary Tract Infection – UTI



unyvero  
a product by curetis



# Hospitalized Pneumonia

Fast & Simple Syndromic Testing for Severe Infections - Improving Patient Outcomes



Unyvero L4 Lysator



Unyvero C8 Cockpit



Unyvero A50 Analyzer

The Unyvero System is distributed on an exclusive basis by A.Menarini Diagnostics in the following countries: Benelux, France, Germany, Greece, Italy, Portugal, Spain, United Kingdom.

Distributed by: A.Menarini Diagnostics S.r.l.

Legal Site: Via Sette Santi, 3 - 50131 Florence, Italy - Operative Site: Via Lungo L'Emma, 7 - 50012 Bagno a Ripoli (FI), Italy - Website: www.menarini.com

- BENELUX - MENARINI BENELUX N.V./S.A: Division Diagnostics De Kleetlaan 3/1831 Machelen/Belgium  
Tel. 0032-2-721 49 30 - Fax 0032-2-721 50 49
- FRANCE - A. MENARINI DIAGNOSTICS FRANCE S.A.S.U.: 3 - 5, rue du Jura BP 70511 F-94633 Rungis Cédex  
Tel. 0033-1-56 34 69 10 - Fax 0033-1-56 34 69 11
- GERMANY - A. MENARINI DIAGNOSTICS DEUTSCHLAND: Division der BERLIN-CHEMIE AG Glienicke Weg 125 D-12489 Berlin  
Tel. 0049-30-6707 3000 Fax 0049-30-6707 3020
- GREECE - MENARINI DIAGNOSTICS S.A.: 575, Vouliagmenis Ave. GR-164 51 Argyroupolis - Athens  
Tel. 0030-210-99 44 952 - Fax 0030-210-99 45 029
- ITALY - A. MENARINI DIAGNOSTICS S.r.l.: Via Lungo l'Emma, 7 50012 Bagno a Ripoli (Firenze)  
Tel. 0039-055-5680-422/394 - Fax 0039-055-5680-905
- PORTUGAL - MENARINI DIAGNOSTICOS LDA: Quinta da Fonte Edifício D, Manuel I, 2º B 2770-203 Paço de Arcos - Lisbon  
Tel. 00351-210-930 000 - Fax 00351-210-930 001
- SPAIN - MENARINI DIAGNOSTICOS S.A.: Avenida del Maresme, 120 08918 Badalona (Barcelona)  
Tel. 0034-93-50 71 000 - Fax 0034-93-27 80 215
- UK - A. MENARINI DIAGNOSTICS LTD: 405 Wharfedale Road Winnersh, Wokingham Berkshire RG41 5RA  
Tel. 0044-118 944 4100 - Fax 0044-118 944 4111

Caution - Investigational Device. Limited by Federal US Law to investigational Use. Not available for Sale in the United States.

FOR PROFESSIONAL USE ONLY Cod. 51257



## Antibiotic resistance threatens the effective treatment of pneumonia<sup>1</sup>

- Nosocomial pneumonia is among the most difficult complications to diagnose.<sup>2</sup>
- Traditional test results take too long, delaying effective treatment.
- Antimicrobial resistance makes the choice of initial antibiotics a major challenge.<sup>3</sup>
- Empiric broad spectrum antibiotics may not provide optimal coverage and exacerbate resistance.<sup>3</sup>

Lower respiratory infections have a mortality rate of over 30% and cost billions.<sup>4</sup>

- WHO report confirms the serious situation of antibiotic resistance worldwide.<sup>5</sup>
- Mortality and costs are expected to rise with increasing antibiotic resistance.

## Faster detection enables earlier optimization of therapy

The Unyvero HPN Application simultaneously identifies a large panel of bacteria, fungi and antibiotic resistance genes.

Unyvero HPN detects the most dangerous and highly resistant microorganisms defined by WHO:

- Pathogens causing severe forms of pneumonia, e.g. *Pseudomonas aeruginosa*
- Pathogens carrying antibiotic resistance e.g. *Klebsiella pneumoniae* and *Acinetobacter baumannii* complex
- Infections with multidrug-resistant bacteria, which may not be targeted by empirical treatment

## Clinical evidence demonstrates the potential benefits provided by the Unyvero solution

### Study 1


University College London, Royal Free Campus, London, UK.  
Comparing Unyvero HPN to traditional culture.

Number of samples  
85 respiratory samples (sputum, tracheal aspirate, bronchoalveolar lavage).

Eligibility  
Hospitalized patients with pneumonia.

4-5 Turnaround time

Mean turnaround time from specimens received to results from the routine laboratory was 53 h (range 21 h–166 h).



94.9% Specificity

88.8% Sensitivity

Unyvero identified more potential pathogens per specimen than routine culture (1.34 vs. 0.47 per specimen)

Ozongwu et al., *Biomol Detect Quantif*, 2017;13:1-6. Investigational device. Not available in the US.

## Unyvero Hospitalized Pneumonia (HPN) Cartridge

Gram-positive bacteria	Enterobacteriaceae	Non-fermenting bacteria	Others / Fungi	Resistance Gene
<i>Staphylococcus aureus</i> <i>Streptococcus pneumoniae</i>	<i>Citrobacter freundii</i> <i>Escherichia coli</i> <i>Enterobacter cloacae</i> complex <i>Klebsiella aerogenes</i> ( <i>E. aerogenes</i> ) <i>Proteus</i> spp. <i>Klebsiella pneumoniae</i> <i>Klebsiella oxytoca</i> <i>Klebsiella variicola</i> <i>Serratia marcescens</i> <i>Morganella morganii</i>	<i>Moraxella catarrhalis</i> <i>Pseudomonas aeruginosa</i> <i>Acinetobacter baumannii</i> complex <i>Stenotrophomonas maltophilia</i> <i>Legionella pneumophila</i>	<i>Pneumocystis jirovecii</i> <i>Haemophilus influenzae</i> <i>Mycoplasma pneumoniae</i> <i>Chlamydia pneumoniae</i>	Macrolide/Lincosamide <i>ermB</i> Oxacillin <i>mecA</i> <i>mecC</i> Penicillin <i>tem</i> <i>shv</i> 3rd generation Cephalosporins <i>ctx-M</i>  <i>kpc</i> <i>imp</i> <i>ndm</i> <i>oxa-23</i> <i>oxa-24/40</i> <i>oxa-48</i> <i>oxa-58</i> <i>vim</i> Carbapenem  Sulfonamide <i>sul1</i> Fluoroquinolone <i>gyrA83</i> <i>gyrA87</i>

### Study 2

Multicenter US clinical trial at nine major hospitals.

Number of samples  
>2000 tracheal aspirate and lavage (BAL/miniBAL) specimens.

Eligibility  
Hospitalized adults with suspicion of lower respiratory tract infection.

Atypical pathogens: High clinical significance, difficult to culture

- Not routinely ordered or tested.
- Not covered by empiric therapy for hospitalized pneumonia.
- Unsuspected cases were detected using Unyvero including 5 confirmed cases of *Mycoplasma pneumoniae*.

Negative cultures

- Unyvero results are not affected by prior antibiotic treatment.

### Conclusion

Unyvero expands the diagnostic capability of pneumonia through rapid microorganism identification and simultaneous detection of associated resistance markers.

91.4% Sensitivity

99.5% Specificity

Transferable Resistance markers  
Overall PPA 89.9%  
Overall NPA 99.3%

Agarwal et al., *ASM Microbe* 2017. US clinical trial. Investigational device. Not available in EMEA. PPA: positive percent agreement; NPA: negative percent agreement

#### Sample Types

Sputum, bronchoalveolar lavage, tracheal aspirates.



Easy Workflow



Multiple Sample Types



24/7 Results